AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02203734 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light Pressure Massage
Description: The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
Study NCT05759507 — intervention group
Intervention type: PROCEDURE
Intervention: abdominal surgery
Study NCT04686461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds extract containing ointment intervention
Description: Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol
Study NCT00980187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
Study NCT00980187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide
Description: 1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
Study NCT01413035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: 1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
Study NCT03167892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral screen
Description: Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
Study NCT00582361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Dressing
Description: Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
Study NCT00582361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC
Description: Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT03718130 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)
Description: The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study NCT05010603 — intervention group
Intervention type: OTHER
Intervention: Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
Description: Memory Test
Study NCT01054508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nicotinic acid/laropiprant
Description: Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
Study NCT04483700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily
Study NCT04949347 — intervention group
Intervention type: BIOLOGICAL
Intervention: glaucoma drainage device implantation
Description: Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
Study NCT04783831 — intervention group
Intervention type: DEVICE
Intervention: Biodegradable stent
Description: Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.
Study NCT01856777 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative panel test
Study NCT01856777 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High sensitivity urine pregnancy test
Study NCT03990831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional near-infrared spectroscopy (fNIRS)
Description: Functional near-infrared spectroscopy (fNIRS) measurement
Study NCT02869854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
Study NCT02869854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
Study NCT02869854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAP
Description: Physical Activity on Prescription, after 3 months a new prescription
Study NCT02869854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAP
Description: Physical Activity on Prescription, after 3 months a new prescription
Study NCT02813629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.
Study NCT03253679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT00006016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00006016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given transarterially (chemoembolization)
Study NCT02813629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.
Study NCT00006016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04567069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Blood samples will be collected twice, 60-120ml/ time. The 1st collection will occur 5 days before the 1st DC vaccine injection, the 2nd collection will occur 15 days after the 1st injection.~Six subcutaneous(ih) injections of DC vaccine will be given at days 1, 8, 15, 21, 28, 35; 1-3×106 cells/time.~Injection site: inguinal lymph nodes.
Study NCT04567069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.
Study NCT04567069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: The Sintilimab Injection (3mg/kg) will be administered by intravenous (iv) drip injection at days 0, 20。
Study NCT03926286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMP-30
Description: FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
Study NCT00402857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Program
Description: The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
Study NCT00402857 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incredible Years Program
Description: The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
Study NCT00471055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0125% Capsaicin gel CAPSIKA gel
Study NCT00471055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00829738 — intervention group
Intervention type: DRUG
Intervention: Pantoprazole
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
Study NCT03467958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study NCT03642873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humibid®
Description: Humibid® 1200 mg (single extended release) tablet
Study NCT03642873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone Bitartrate
Description: Hydrocodone Bitartrate (3.33 mg q4h X 3)
Study NCT03642873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humibid® and Hydrocodone Bitartrate tablet
Description: Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
Study NCT03819985 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT
Study NCT03819985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03819985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02433626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COTI2
Description: COTI-2 is a third generation thiosemicarbazone.
Study NCT02433626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is approved to treat a range of solid tumors and lymphomas.
Study NCT00844844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study NCT03905096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film coated tablet
Study NCT03905096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Film coated tablet
Study NCT02512549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Study NCT02560259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy
Study NCT02560259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Study NCT02914158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Study NCT03844555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole(MTZ)
Description: Metronidazole 500 mg twice daily
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 twice daily
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 twice daily
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: KLacid twice daily
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: KLacid twice daily
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Tavanic. Tavacin
Study NCT02422706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxicycline
Description: Vibramycin 100 mg twice daily
Study NCT02753166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
Study NCT02398916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Study NCT01456286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
Study NCT01456286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sapropterin
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
Study NCT01703078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol once daily for two consecutive days
Study NCT01703078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol once daily for two consecutive days
Study NCT01131988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Capsules
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Study NCT01131988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Capsules
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Study NCT05360927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection
Study NCT05360927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study NCT04564846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801
Description: 8 mg capsules of ORMD-0801 (Oral Insulin)
Study NCT04564846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (Fish Oil)
Study NCT02574403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: eculizumab discontinuation
Study NCT02216669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTP348
Description: Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
Study NCT04086017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Description: Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
Study NCT01766050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT01766050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Study NCT01766050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT01766050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Study NCT01766050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01766050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII
Study NCT03029806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII
Study NCT04277949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium:YAG
Description: Treatment with Erbium:YAG laser
Study NCT04277949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV endonuclease from Micrococcus luteus
Description: Application of topical DNA repair enzymes
Study NCT03496493 — intervention group
Intervention type: DEVICE
Intervention: All patients
Description: Peripheral arterial oxygen saturation recording with both study devices
Study NCT01704027 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost intensity-modulated arctherapy
Description: Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)
Study NCT01704027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
Study NCT03212326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]
Description: Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.